42 related articles for article (PubMed ID: 1718855)
1. Directed evolution of broadly crossreactive chemokine-blocking antibodies efficacious in arthritis.
Angelini A; Miyabe Y; Newsted D; Kwan BH; Miyabe C; Kelly RL; Jamy MN; Luster AD; Wittrup KD
Nat Commun; 2018 Apr; 9(1):1461. PubMed ID: 29654232
[TBL] [Abstract][Full Text] [Related]
2. Targeted Fcγ Receptor (FcγR)-mediated Clearance by a Biparatopic Bispecific Antibody.
Kasturirangan S; Rainey GJ; Xu L; Wang X; Portnoff A; Chen T; Fazenbaker C; Zhong H; Bee J; Zeng Z; Jenne C; Wu H; Gao C
J Biol Chem; 2017 Mar; 292(10):4361-4370. PubMed ID: 28100773
[TBL] [Abstract][Full Text] [Related]
3. G-CSF/anti-G-CSF antibody complexes drive the potent recovery and expansion of CD11b+Gr-1+ myeloid cells without compromising CD8+ T cell immune responses.
Rubinstein MP; Salem ML; Doedens AL; Moore CJ; Chiuzan C; Rivell GL; Cole DJ; Goldrath AW
J Hematol Oncol; 2013 Oct; 6():75. PubMed ID: 24279871
[TBL] [Abstract][Full Text] [Related]
4. A mathematical model for selective differentiation of neural progenitor cells on micropatterned polymer substrates.
Howk CL; Levine HA; Smiley MW; Mallapragada SK; Nilsen-Hamilton M; Oh J; Sakaguchi DS
Math Biosci; 2012 Aug; 238(2):65-79. PubMed ID: 22569338
[TBL] [Abstract][Full Text] [Related]
5. Human monoclonal antibodies targeting nonoverlapping epitopes on insulin-like growth factor II as a novel type of candidate cancer therapeutics.
Chen W; Feng Y; Zhao Q; Zhu Z; Dimitrov DS
Mol Cancer Ther; 2012 Jul; 11(7):1400-10. PubMed ID: 22553356
[TBL] [Abstract][Full Text] [Related]
6. The antimelanoma immunocytokine scFvMEL/TNF shows reduced toxicity and potent antitumor activity against human tumor xenografts.
Liu Y; Zhang W; Cheung LH; Niu T; Wu Q; Li C; Van Pelt CS; Rosenblum MG
Neoplasia; 2006 May; 8(5):384-93. PubMed ID: 16790087
[TBL] [Abstract][Full Text] [Related]
7. Antibody buffering of a ligand in vivo.
O'Hear CE; Foote J
Proc Natl Acad Sci U S A; 2005 Jan; 102(1):40-4. PubMed ID: 15615858
[TBL] [Abstract][Full Text] [Related]
8. Endogenous interleukin 6 production in multiple myeloma patients treated with chimeric monoclonal anti-IL6 antibodies indicates the existence of a positive feed-back loop.
van Zaanen HC; Koopmans RP; Aarden LA; Rensink HJ; Stouthard JM; Warnaar SO; Lokhorst HM; van Oers MH
J Clin Invest; 1996 Sep; 98(6):1441-8. PubMed ID: 8823310
[TBL] [Abstract][Full Text] [Related]
9. Administration of neutralizing antibodies to interleukin-6 (IL-6) reduces experimental autoimmune encephalomyelitis and is associated with elevated levels of IL-6 bioactivity in central nervous system and circulation.
Gijbels K; Brocke S; Abrams JS; Steinman L
Mol Med; 1995 Nov; 1(7):795-805. PubMed ID: 8612202
[TBL] [Abstract][Full Text] [Related]
10. Induction of autoimmune disease by graft-versus-host reaction across MHC class II difference: modification of the lesions in IL-6 transgenic mice.
Kimura T; Suzuki K; Inada S; Hayashi A; Saito H; Miyai T; Ohsugi Y; Matsuzaki Y; Tanaka N; Osuga T
Clin Exp Immunol; 1994 Mar; 95(3):525-9. PubMed ID: 8137550
[TBL] [Abstract][Full Text] [Related]
11. An antimelanoma immunotoxin containing recombinant human tumor necrosis factor: tissue disposition, pharmacokinetic, and therapeutic studies in xenograft models.
Rosenblum MG; Cheung L; Mujoo K; Murray JL
Cancer Immunol Immunother; 1995 May; 40(5):322-8. PubMed ID: 7600565
[TBL] [Abstract][Full Text] [Related]
12. Production, characterization and use of five monoclonal antibodies to human IL-4.
Scott MG; Levine AD; Butch AW; Bowen MB; Macke KA; Nahm MH
Lymphokine Res; 1990; 9(1):81-93. PubMed ID: 1691418
[TBL] [Abstract][Full Text] [Related]
13. Human interleukin-6 is in vivo an autocrine growth factor for human herpesvirus-8-infected malignant B lymphocytes.
Foussat A; Wijdenes J; Bouchet L; Gaidano G; Neipel F; Balabanian K; Galanaud P; Couderc J; Emilie D
Eur Cytokine Netw; 1999 Dec; 10(4):501-8. PubMed ID: 10586116
[TBL] [Abstract][Full Text] [Related]
14. Effects of PEGylation and immune complex formation on the pharmacokinetics and biodistribution of recombinant interleukin 10 in mice.
Alvarez HM; So OY; Hsieh S; Shinsky-Bjorde N; Ma H; Song Y; Pang Y; Marian M; Escandón E
Drug Metab Dispos; 2012 Feb; 40(2):360-73. PubMed ID: 22083830
[TBL] [Abstract][Full Text] [Related]
15. Therapeutic potential of humanized anti-interleukin-6 receptor antibody: antitumor activity in xenograft model of multiple myeloma.
Tsunenari T; Akamatsu K; Kaiho S; Sato K; Tsuchiya M; Koishihara Y; Kishimoto T; Ohsugi Y
Anticancer Res; 1996; 16(5A):2537-44. PubMed ID: 8917348
[TBL] [Abstract][Full Text] [Related]
16. Murine anti-human IL-6 monoclonal antibody prolongs the half-life in circulating blood and thus prolongs the bioactivity of human IL-6 in mice.
Mihara M; Koishihara Y; Fukui H; Yasukawa K; Ohsugi Y
Immunology; 1991 Sep; 74(1):55-9. PubMed ID: 1718855
[TBL] [Abstract][Full Text] [Related]
17. Comparative activity of Sant7 and anti-IL-6, IL-6R monoclonal antibodies in a murine model of B-cell lymphoma.
Campo S; Serlupi-Crescenzi O; Arseni B; Rossi S; Saggio I; Salone B; Cherubini G; Carminati P; De Santis R
Cytokine; 2005 Sep; 31(5):368-74. PubMed ID: 16061391
[TBL] [Abstract][Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
